摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-氰基-2-甲基-6-(甲基硫代)嘧啶-4(3H)-酮 | 15908-63-1

中文名称
5-氰基-2-甲基-6-(甲基硫代)嘧啶-4(3H)-酮
中文别名
——
英文名称
2-methyl-4-methylsulfanyl-6-oxo-1H-pyrimidine-5-carbonitrile
英文别名
1,4-dihydro-2-methyl-6-(methylthio)-4-oxo-5-pyrimidinecarbonitrile
5-氰基-2-甲基-6-(甲基硫代)嘧啶-4(3H)-酮化学式
CAS
15908-63-1
化学式
C7H7N3OS
mdl
MFCD00067845
分子量
181.22
InChiKey
SSWJKGVCZRWCAF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 溶解度:
    >27.2 [ug/mL]

计算性质

  • 辛醇/水分配系数(LogP):
    -0.1
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.285
  • 拓扑面积:
    90.6
  • 氢给体数:
    1
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2933599090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:499aab55e7e3ef8d9ac1e269acc49156
查看

反应信息

点击查看最新优质反应信息

文献信息

  • MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
    申请人:Constellation Pharmaceuticals, Inc.
    公开号:US20190322651A1
    公开(公告)日:2019-10-24
    Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with methyl modifying enzymes. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with methyl modifying enzymes.
    提供了式(I)的新化合物及其药用盐,这些化合物对治疗与甲基修饰酶相关的各种疾病、疾病或症状有用。还提供了包括式(I)的新化合物、其药用盐的药物组合物,以及治疗与甲基修饰酶相关的一种或多种疾病、疾病或症状的使用方法。
  • 2,4-disubstituted-5-cyano-1,6-dihydro-6-oxo-1-pyrimidineacetic acid
    申请人:American Home Products Corporation
    公开号:US04786638A1
    公开(公告)日:1988-11-22
    Disclosed herein are 2,4-disubstituted-5-cyano-1,6-dihydro-6-oxo-1-pyrimidineacetic acids and pharmaceutically acceptable salts thereof and methods of their preparation. The compounds are new aldose reductase inhibitors useful for the treatment or prevention of diabetic complications.
    本文披露了2,4-二取代-5-氰基-1,6-二氢-6-氧-1-嘧啶乙酸及其药用盐,以及它们的制备方法。这些化合物是新的醛糖还原酶抑制剂,可用于治疗或预防糖尿病并发症。
  • Amino-pyrimidine derivatives
    申请人:AMERICAN HOME PRODUCTS CORPORATION
    公开号:EP0130735A1
    公开(公告)日:1985-01-09
    The invention concerns compounds of the formula I in which R' is lower alkyl, cyclo(lower)alkyl, phenyl(lower)alkyl, or trifluoromethyl; R2 is oxo, thioxo or imino; R3 is cyano, aminocarbonyl, nitro, methylsulfonyl or aminosulfonyl; R4, R5, R6, R7 and R8 each independently is hydrogen or lower alkyl; R9 is hydrogen, lower alkenyl, 1-piperidinyl, 1-pyrrolidinyl, 1-piperazinyl, lower alkynyl, cyclo(lower)alkyl, 2, 3 or 4-pyridinyl, 2 or 3-furanyl, 2 or 3-indolyl, 2 or 3-thienyl, 5-imidazolyl, 4-morpholinyl, phenyl, phenyl mono- or disubstituted with hydroxy or lower alkoxy, 4-thiomorpholinyl, pyrazinyl, pyridazinyl, triazinyl, pyrrolyl, pyrazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, isoxazolyl, furazolyl, oxathiazolyl, quinolinyl, isoquinolinyl, pyridopyrimidinyl, benzoxazolyl, benzimidazolyl, benzthiazolyl, benzoxazinyl, benzpyronyl, isoindolyl, or indolazinyl; and m and n each independently is an integer 0 to 2; or a therapeutically acceptable addition salt thereof for use in increasing cardiac contractility in mammals. Processes for their preparation and pharmaceutical compositions containing them also disclosed.
    本发明涉及式 I 的化合物 其中,R'为低级烷基、环(低级)烷基、苯基(低级)烷基或三氟甲基;R2为氧代、硫代或亚氨基;R3为氰基、氨基羰基、硝基、甲磺酰基或氨基磺酰基;R4、R5、R6、R7和R8各自独立地为氢或低级烷基;R9 是氢、低级烯基、1-哌啶基、1-吡咯烷基、1-哌嗪基、低级炔基、环(低级)烷基、2、3 或 4-吡啶基、2 或 3-呋喃基、2 或 3-吲哚基、2 或 3-噻吩基、5-咪唑基、4-吗啉基、苯基、与羟基或低级烷氧基单取代或二取代的苯基、4-硫代吗啉基、吡嗪基、哒嗪基、三嗪基、吡咯基、吡唑基、噻唑基、噁二唑基、噻二唑基、异噁唑基、呋喃唑基、噁硫唑基、喹啉基、异喹啉基、吡啶嘧啶基、苯并噁唑基、苯并咪唑基、苯并噻唑基、苯并噁嗪基、苯并吡喃基、异吲哚基或吲哚嗪基;m和n各自独立地为0至2的整数;或其治疗上可接受的添加盐,用于增加哺乳动物的心脏收缩力。还公开了其制备方法和含有它们的药物组合物。
  • Modulators of methyl modifying enzymes, compositions and uses thereof
    申请人:Constellation Pharmaceuticals, Inc.
    公开号:US10689371B2
    公开(公告)日:2020-06-23
    Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with methyl modifying enzymes. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with methyl modifying enzymes.
    本文提供了新型的式 (I) 化合物: 及其药学上可接受的盐,可用于治疗与甲基修饰酶有关的各种疾病、失调或病症。此外,还提供了包含式(I)新型化合物、其药学上可接受的盐类的药物组合物,及其用于治疗一种或多种与甲基修饰酶相关的疾病、失调或病症的方法。
  • Kohra, Shinya; Tominaga, Yoshinori; Hosomi, Akira, Journal of Heterocyclic Chemistry, 1988, vol. 25, p. 959 - 968
    作者:Kohra, Shinya、Tominaga, Yoshinori、Hosomi, Akira
    DOI:——
    日期:——
查看更多